NCT06278038View on ClinicalTrials.gov

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder

NACompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 22, 2024

Primary Completion Date

November 10, 2024

Study Completion Date

November 19, 2024

Conditions
Major Depression Disorder
Interventions
DRUG

Toludesvenlafaxine hydrochloride sustained-release tablets

80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks

DRUG

Venlafaxine hydrochloride sustained-release tablets

75 mg or 150 mg or 225 mg orally once daily dosing for 8 weeks

Trial Locations (1)

310009

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER

NCT06278038 - Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder | Biotech Hunter | Biotech Hunter